Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Inmune Bio, Inc.INMB · Entity 7094 | 10% owner | June 10, 2021 | September 08, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Inmune Bio, Inc.
Report date June 10, 2021 · Filed September 08, 2021 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,777,533 |
Reported balance
After 2021-06-10 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2021-06-10 · Other · Acquired 192,533 · Balance 1,777,533 F1: On October 3, 2017, INmune Bio Inc. ("INmune") entered into a license agreement ("Xencor License Agreement") with Xencor, Inc. ("Xencor"). In connection with the Xencor License Agreement, INmune granted Xencor an option to purchase an additional number of shares of common stock equal to 10% of the fully diluted company shares immediately following such purchase (the "Option"). On June 10, 2021, INmune entered into an Option Cancellation Agreement with Xencor, pursuant to which Xencor agreed to cancel the Option and terminate certain other rights in exchange for these shares and $15,000,000. The number of shares was determined by dividing $3.3 million by the closing price of INmune's common stock on June 10, 2021. F2: On June 14, 2021, Xencor filed a Form 4 which inadvertently reported that Xencor acquired 192,532 shares of common stock in the Option Cancellation Transaction. As reported in this amendment, Xencor actually acquired 192,533 shares of common stock in the Option Cancellation Transaction. The original Form 4 also inadvertently indicated that Xencor beneficially owned 1,777,532 shares of common stock following the Option Cancellation Transaction, but Xencor actually beneficially owned 1,777,533 shares of common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: On October 3, 2017, INmune Bio Inc. ("INmune") entered into a license agreement ("Xencor License Agreement") with Xencor, Inc. ("Xencor"). In connection with the Xencor License Agreement, INmune granted Xencor an option to purchase an additional number of shares of common stock equal to 10% of the fully diluted company shares immediately following such purchase (the "Option"). On June 10, 2021, INmune entered into an Option Cancellation Agreement with Xencor, pursuant to which Xencor agreed to cancel the Option and terminate certain other rights in exchange for these shares and $15,000,000. The number of shares was determined by dividing $3.3 million by the closing price of INmune's common stock on June 10, 2021.
F2: On June 14, 2021, Xencor filed a Form 4 which inadvertently reported that Xencor acquired 192,532 shares of common stock in the Option Cancellation Transaction. As reported in this amendment, Xencor actually acquired 192,533 shares of common stock in the Option Cancellation Transaction. The original Form 4 also inadvertently indicated that Xencor beneficially owned 1,777,532 shares of common stock following the Option Cancellation Transaction, but Xencor actually beneficially owned 1,777,533 shares of common stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 03, 2021 Filed Sep 8, 2021 20:15 UTC | Inmune Bio, Inc. INMB · Entity 7094 | Exercise / conversionStock Option (Right to Buy) · Derivative | 108,000 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001415889-21-004281 · form4-09082021_040906.xml · derivative · entry 2 Xencor Inc · CIK 0001326732 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 108,000 shares Expires 2021-09-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares underlying this option vested in 36 equal monthly installments beginning on April 3, 2018. Read SEC document |
| September 03, 2021 Filed Sep 8, 2021 20:15 UTC | Inmune Bio, Inc. INMB · Entity 7094 | Exercise / conversionCommon Stock | 108,000 | $7.80 | $842,400.00 |
DisclosureSEC source: 0001415889-21-004281 · form4-09082021_040906.xml · nonDerivative · entry 1 Xencor Inc · CIK 0001326732 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,885,533 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 10, 2021 Filed Jun 14, 2021 20:47 UTC | Inmune Bio, Inc. INMB · Entity 7094 | OtherCommon Stock | 192,532 | $17.14 | $3,299,998.48 |
DisclosureSEC source: 0001415889-21-002991 · form4-06142021_010635.xml · nonDerivative · entry 1 Xencor Inc · CIK 0001326732 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: Not disclosed F1 · kind: On October 3, 2017, INmune Bio Inc. ("INmune") entered into a license agreement ("Xencor License Agreement") with Xencor, Inc. ("Xencor"). In connection with the Xencor License Agreement, INmune granted Xencor an option to purchase an additional number of shares of common stock equal to 10% of the fully diluted company shares immediately following such purchase (the "Option"). On June 10, 2021, INmune entered into an Option Cancellation Agreement with Xencor, pursuant to which Xencor agreed to cancel the Option and terminate certain other rights in exchange for these shares and $15,000,000. The number of shares was determined by dividing $3.3 million by the closing price of INmune's common stock on June 10, 2021. F1 · price: On October 3, 2017, INmune Bio Inc. ("INmune") entered into a license agreement ("Xencor License Agreement") with Xencor, Inc. ("Xencor"). In connection with the Xencor License Agreement, INmune granted Xencor an option to purchase an additional number of shares of common stock equal to 10% of the fully diluted company shares immediately following such purchase (the "Option"). On June 10, 2021, INmune entered into an Option Cancellation Agreement with Xencor, pursuant to which Xencor agreed to cancel the Option and terminate certain other rights in exchange for these shares and $15,000,000. The number of shares was determined by dividing $3.3 million by the closing price of INmune's common stock on June 10, 2021. Read SEC document |
| June 10, 2021 Filed Sep 8, 2021 20:15 UTC Amendment | Inmune Bio, Inc. INMB · Entity 7094 | OtherCommon Stock | 192,533 | $17.14 | $3,300,015.62 |
DisclosureSEC source: 0001415889-21-004280 · form4a-09082021_040901.xml · nonDerivative · entry 1 Xencor Inc · CIK 0001326732 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,777,533 F1 · kind: On October 3, 2017, INmune Bio Inc. ("INmune") entered into a license agreement ("Xencor License Agreement") with Xencor, Inc. ("Xencor"). In connection with the Xencor License Agreement, INmune granted Xencor an option to purchase an additional number of shares of common stock equal to 10% of the fully diluted company shares immediately following such purchase (the "Option"). On June 10, 2021, INmune entered into an Option Cancellation Agreement with Xencor, pursuant to which Xencor agreed to cancel the Option and terminate certain other rights in exchange for these shares and $15,000,000. The number of shares was determined by dividing $3.3 million by the closing price of INmune's common stock on June 10, 2021. F2 · shares: On June 14, 2021, Xencor filed a Form 4 which inadvertently reported that Xencor acquired 192,532 shares of common stock in the Option Cancellation Transaction. As reported in this amendment, Xencor actually acquired 192,533 shares of common stock in the Option Cancellation Transaction. The original Form 4 also inadvertently indicated that Xencor beneficially owned 1,777,532 shares of common stock following the Option Cancellation Transaction, but Xencor actually beneficially owned 1,777,533 shares of common stock. F1 · price: On October 3, 2017, INmune Bio Inc. ("INmune") entered into a license agreement ("Xencor License Agreement") with Xencor, Inc. ("Xencor"). In connection with the Xencor License Agreement, INmune granted Xencor an option to purchase an additional number of shares of common stock equal to 10% of the fully diluted company shares immediately following such purchase (the "Option"). On June 10, 2021, INmune entered into an Option Cancellation Agreement with Xencor, pursuant to which Xencor agreed to cancel the Option and terminate certain other rights in exchange for these shares and $15,000,000. The number of shares was determined by dividing $3.3 million by the closing price of INmune's common stock on June 10, 2021. F2 · balance_after: On June 14, 2021, Xencor filed a Form 4 which inadvertently reported that Xencor acquired 192,532 shares of common stock in the Option Cancellation Transaction. As reported in this amendment, Xencor actually acquired 192,533 shares of common stock in the Option Cancellation Transaction. The original Form 4 also inadvertently indicated that Xencor beneficially owned 1,777,532 shares of common stock following the Option Cancellation Transaction, but Xencor actually beneficially owned 1,777,533 shares of common stock. Read SEC document |
| June 10, 2021 Filed Sep 8, 2021 20:15 UTC Amendment | Inmune Bio, Inc. INMB · Entity 7094 | OtherCommon Stock | 192,533 | $17.14 | $3,300,015.62 |
DisclosureSEC source: 0001415889-21-004279 · form4a-09082021_040901.xml · nonDerivative · entry 1 Xencor Inc · CIK 0001326732 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,777,533 F1 · kind: On October 3, 2017, INmune Bio Inc. ("INmune") entered into a license agreement ("Xencor License Agreement") with Xencor, Inc. ("Xencor"). In connection with the Xencor License Agreement, INmune granted Xencor an option to purchase an additional number of shares of common stock equal to 10% of the fully diluted company shares immediately following such purchase (the "Option"). On June 10, 2021, INmune entered into an Option Cancellation Agreement with Xencor, pursuant to which Xencor agreed to cancel the Option and terminate certain other rights in exchange for these shares and $15,000,000. The number of shares was determined by dividing $3.3 million by the closing price of INmune's common stock on June 10, 2021. F2 · shares: On June 14, 2021, Xencor filed a Form 4 which inadvertently reported that Xencor acquired 192,532 shares of common stock in the Option Cancellation Transaction. As reported in this amendment, Xencor actually acquired 192,533 shares of common stock in the Option Cancellation Transaction. The original Form 4 also inadvertently indicated that Xencor beneficially owned 1,777,532 shares of common stock following the Option Cancellation Transaction, but Xencor actually beneficially owned 1,777,533 shares of common stock. F1 · price: On October 3, 2017, INmune Bio Inc. ("INmune") entered into a license agreement ("Xencor License Agreement") with Xencor, Inc. ("Xencor"). In connection with the Xencor License Agreement, INmune granted Xencor an option to purchase an additional number of shares of common stock equal to 10% of the fully diluted company shares immediately following such purchase (the "Option"). On June 10, 2021, INmune entered into an Option Cancellation Agreement with Xencor, pursuant to which Xencor agreed to cancel the Option and terminate certain other rights in exchange for these shares and $15,000,000. The number of shares was determined by dividing $3.3 million by the closing price of INmune's common stock on June 10, 2021. F2 · balance_after: On June 14, 2021, Xencor filed a Form 4 which inadvertently reported that Xencor acquired 192,532 shares of common stock in the Option Cancellation Transaction. As reported in this amendment, Xencor actually acquired 192,533 shares of common stock in the Option Cancellation Transaction. The original Form 4 also inadvertently indicated that Xencor beneficially owned 1,777,532 shares of common stock following the Option Cancellation Transaction, but Xencor actually beneficially owned 1,777,533 shares of common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.